Evidence map›Paper›PMID 27188181›Full record

ReviewCurrent heart failure reports2016

Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.

Ersilia M DeFilippis, Michael M Givertz

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current heart failure reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ersilia M DeFilippisDepartment of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Michael M GivertzCardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. mgivertz@partners.org.
Brigham and Women's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past two decades, therapeutics for diabetes have evolved from drugs with known heart failure risk to classes with potential benefit for patients with heart failure. As many as 25 to 35 % of patients with heart failure carry a diagnosis of type 2 diabetes mellitus. Therefore, newer drug classes including dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 (GIP-1) agonists, and sodium-glucose cotransporter 2 (SGLT-2) inhibitors are being examined for cardiovascular safety as well as their effects on left ventricular function, quality of life, and other measures of disease progression. The purpose of this review is to summarize the existing evidence on these classes of anti-diabetic agents in patients with heart failure.

Indexed as

Sodium-Glucose Transporter 2 InhibitorsBlood GlucoseDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDisease ProgressionGlucagon-Like Peptide 1Heart FailureHumansHypoglycemic AgentsQuality of LifeSodium-Glucose Transporter 2Ventricular Function, LeftBlood GlucoseDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide 1Hypoglycemic AgentsSLC5A2 protein, humanSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsDiabetesDipeptidyl peptidase 4 inhibitorGlucagon-like peptide 1 agonistHeart failureInsulin resistanceSodium-glucose cotransporter 2 inhibitor

Identifiers

PMID27188181
OpenAlexW2405201497

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.